Assessment of mouse VEGF neutralization by ranibizumab and aflibercept.
PLoS ONE, 2022 PurposeTo assess the interaction between ranibizumab, aflibercept, and mouse vascular endothelial growth factor (VEGF), both in vivo and in vitro.MethodsIn vivo, the effect of intravitreal injection of ranibizumab and aflibercept on oxygen induced ...
Yusuke Ichiyama +7 more
doaj +2 more sources
Comparison of Three Consecutive Monthly Administrations Between Aflibercept 8 mg and Brolucizumab 6 mg in Polypoidal Choroidal Vasculopathy [PDF]
PharmaceuticalsPurpose: The aim was to compare the short-term outcomes of aflibercept 8 mg and brolucizumab for the treatment of polypoidal choroidal vasculopathy (PCV). Methods: This study included 48 eyes of 48 patients with PCV.
Yoshiko Fukuda +4 more
doaj +2 more sources
High-Dose 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration: Who Is Being Treated with This New Agent? [PDF]
LifePurpose: To describe the indication spectrum for high-dose 8 mg aflibercept for neovascular age-related macular degeneration (nAMD) in a real-world cohort in a tertiary referral center.
Caspar Liesenhoff +10 more
doaj +2 more sources
Switching to faricimab from aflibercept during maintenance treatment period for age-related macular degeneration [PDF]
Scientific ReportsTo compare the short-term treatment outcomes of aflibercept and faricimab for neovascular age-related macular degeneration (nAMD) during the maintenance treatment period, we included 82 eyes of 74 patients who switched from aflibercept to faricimab ...
Misa Masaoka, Kenji Yamashiro
doaj +2 more sources
Clinical Cancer Research, 2013 Abstract Aflibercept, an intravenously administered anti-VEGF and antiplacental growth factor (PlGF) agent, has recently been approved by the U.S. Food and Drug Administration in combination with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) for the treatment of patients with metastatic colorectal cancer who have previously ...
Kristen K, Ciombor +2 more
+6 more sources
Bilateral Sterile Intraocular Inflammation Following Intravitreal Aflibercept 8 mg Injections: A Case Report. [PDF]
Reports (MDPI)Cohen R, Kerman T, Trivizki O.
europepmc +3 more sources
Proteome Analysis of Aflibercept Intervention in Experimental Central Retinal Vein Occlusion
Molecules, 2022 Aflibercept is a frequently used inhibitor of vascular endothelial growth factor (VEGF) in the treatment of macular edema following central retinal vein occlusion (CRVO).
Lasse Jørgensen Cehofski +9 more
doaj +1 more source
Journal of Ophthalmology, 2021 Background: Proliferative diabetic retinopathy (PDR) can cause a loss of vision due to complications like vitreous hemorrhage and tractional retinal detachment, which require vitrectomy.
Vira S. Ponomarchuk +2 more
doaj +1 more source
Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA. [PDF]
PLoS ONE, 2015 To compare treatment patterns of intravitreal ranibizumab and aflibercept for the management of neovascular age-related macular degeneration (nAMD) in a real-world setting over the first 12 months of treatment.A proprietary clinical database was used to ...
Alberto Ferreira +5 more
doaj +1 more source
Transient Vision Loss Associated with Prefilled Aflibercept Syringes
Ophthalmology Science, 2022 Purpose: To describe cases of significant vision loss after intravitreal aflibercept administration using prefilled syringes (PFS) and to study the relationships among syringe design, injection speed, and injection force.
Daniel J. Lee, MD +4 more
doaj +1 more source